AstraZeneca is launching a new drug R&D collaboration with CSPC in a deal that could reach up to $1.7 billion, returning to the same Chinese partner within months of a landmark transaction. The UK pharma said it is again teaming up with CSPC to develop therapies. The structure is framed as a renewed biobucks-style partnership focused on discovery and development activities, with deal economics reported at the upper bound of $1.7 billion. The announcement follows AstraZeneca’s recent large-scale China-linked collaboration that helped expand its footprint in the region. For biotech and pharma observers, the repeat-partner approach underscores the role of China-based development collaborations as a strategic lever for global portfolios and development capacity.